The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease

To pursue a systematic approach to the discovery of functional connections among diseases, genetic perturbation, and drug action, we have created the first installment of a reference collection of gene-expression profiles from cultured human cells treated with bioactive small molecules, together with pattern-matching software to mine these data. We demonstrate that this “Connectivity Map” resource can be used to find connections among small molecules sharing a mechanism of action, chemicals and physiological processes, and diseases and drugs. These results indicate the feasibility of the approach and suggest the value of a large-scale community Connectivity Map project.

[1]  A. Chadli.  THE CANCER CELL , 1924, La Presse medicale.

[2]  D. Wolfe,et al.  Nonparametric Statistical Methods. , 1974 .

[3]  W. McGuire,et al.  Phytoestrogen interaction with estrogen receptors in human breast cancer cells. , 1978, Endocrinology.

[4]  J Y Vanderhoek,et al.  Local anesthetics, chlorpromazine and propranolol inhibit stimulus-activation of phospholipase A2 in human platelets. , 1979, Molecular pharmacology.

[5]  D. Edwards,et al.  17α-Estradiol Is a Biologically Active Estrogen in Human Breast Cancer Cells in Tissue Culture* , 1980 .

[6]  C. Geary.  Leukemia , 1984, British Journal of Cancer.

[7]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[8]  S. Khalid,et al.  Isolation and characterization of an antimalarial agent of the neem tree Azadirachta indica. , 1989, Journal of natural products.

[9]  B. Mylari,et al.  1,2-Dihydro-1-oxopyrrolo[3,2,1-kl]phenothiazine-2-carboxamides and congeners, dual cyclooxygenase/5-lipoxygenase inhibitors with antiinflammatory activity. , 1990, Journal of medicinal chemistry.

[10]  R. Pieters,et al.  Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia , 1991, The Lancet.

[11]  A. Wakeling,et al.  A potent specific pure antiestrogen with clinical potential. , 1991, Cancer research.

[12]  AC Tose.  Cell , 1993, Cell.

[13]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[14]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[15]  T. Hongo,et al.  In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. , 1997, Blood.

[16]  P. Brown,et al.  Exploring the metabolic and genetic control of gene expression on a genomic scale. , 1997, Science.

[17]  R. Pieters,et al.  In Vitro Cellular Drug Resistance and Prognosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia , 1997 .

[18]  J. Lehmann,et al.  Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs* , 1997, The Journal of Biological Chemistry.

[19]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[20]  R. Pieters,et al.  Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. , 1998, Blood.

[21]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[22]  Yudong D. He,et al.  Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.

[23]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[24]  R G Ulrich,et al.  Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. , 2001, Toxicology and applied pharmacology.

[25]  K Kosaka,et al.  Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. , 2001, Biochemical and biophysical research communications.

[26]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[27]  T. Poggio,et al.  Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.

[28]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[29]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[30]  K. Glaser,et al.  Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. , 2003, Molecular cancer therapeutics.

[31]  T. Golub,et al.  A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.

[32]  I. P. López,et al.  DNA microarray analysis of genes differentially expressed in diet-induced (cafeteria) obese rats. , 2003, Obesity research.

[33]  T. Larsen,et al.  PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? , 2003, International Journal of Obesity.

[34]  W. Tissing,et al.  Molecular determinants of glucocorticoid sensitivity and resistance in acute lymphoblastic leukemia , 2003, Leukemia.

[35]  G. Gores,et al.  Calpains Can Do It Alone: Implications for Cancer Therapy , 2003, Cancer biology & therapy.

[36]  John H Kersey,et al.  FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  M. Tabaton,et al.  Microarray Analysis in Alzheimer's Disease and Normal Aging , 2004, IUBMB life.

[38]  Kate A. Stafford,et al.  Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Frasor,et al.  Selective Estrogen Receptor Modulators , 2004, Cancer Research.

[40]  E. Hennessy,et al.  Synthesis of 4,5-dianilinophthalimide and related analogues for potential treatment of Alzheimer's disease via palladium-catalyzed amination. , 2005, The Journal of organic chemistry.

[41]  M. Fielden,et al.  Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. , 2005, Journal of biotechnology.

[42]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[43]  Gert R. G. Lanckriet,et al.  Classification of a large microarray data set: algorithm comparison and analysis of drug signatures. , 2005, Genome research.

[44]  M. Fielden,et al.  A Gene Expression Signature that Predicts the Future Onset of Drug-Induced Renal Tubular Toxicity , 2005, Toxicologic pathology.